Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1,1-cyclobutane dicarboxylato (2-)-0,0']-(SP-4-2) in athymic rats with osteosarcoma
| Autor: | Michael G. Conzemius, Joseph S. Haynes, Christine A. Graham, Joanne C. Graham |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Neutrophils medicine.medical_treatment Radioimmunoassay Antineoplastic Agents Bone Neoplasms Statistics Nonparametric Carboplatin Metastasis Rats Sprague-Dawley Leukocyte Count Random Allocation Rats Nude Insulin-like growth factor chemistry.chemical_compound Internal medicine Tumor Cells Cultured medicine Animals Insulin-Like Growth Factor I Saline Osteosarcoma General Veterinary business.industry Growth factor Body Weight General Medicine medicine.disease Survival Analysis Primary tumor Rats Disease Models Animal Endocrinology Somatostatin chemistry Growth Hormone Drug Therapy Combination Female business Neoplasm Transplantation Hormone |
| Zdroj: | American Journal of Veterinary Research. 61:646-650 |
| ISSN: | 0002-9645 |
| DOI: | 10.2460/ajvr.2000.61.646 |
| Popis: | Objective—To determine the effect of exogenous growth hormone or somatostatin on chemotherapeutic efficacy in athymic (nude) rats with osteosarcoma. Animals—66 female athymic rats. Procedure—Osteosarcoma was induced at an intratibial site. Rats were randomly allotted to 6 treatment groups. Rats were treated with saline (0.9% NaCl) solution alone, platinum, diammine [1,1-cyclobutane dicaboxylato (2-)-0,0']-(SP-4-2) (CBDCA; ie, carboplatin) plus saline solution, somatostatin alone, somatostatin plus CBDCA, growth hormone alone, or growth hormone plus CBDCA. Variables measured included estimated WBC count and percentage of neutrophils, plasma concentration of insulin-like growth factor I (IGF-I), body weight, tumor volume, weight of primary tumor, survival time, and distant metastasis at time of death. Results—Tumors formed at the injection sites in all rats. Treatment with growth hormone increased, and treatment with somatostatin decreased, plasma IGF-I concentration. Treatment with growth hormone or somatostatin altered CBDCA efficacy, as determined by evaluation of mean and median survival times. Metastatic pulmonary disease developed in 63 of 64 rats. Conclusions and Clinical Relevance—The technique used here reliably induced local osteosarcomas and metastatic pulmonary disease. Treatment with growth hormone and CBDCA or somatostatin may improve chemotherapeutic efficacy without increasing toxic effects. Implications for Human Medicine—Results reported here may be useful in the study of osteosarcoma in humans. (Am J Vet Res 2000;61:646–650) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|